1. Home
  2. VZLA vs OGN Comparison

VZLA vs OGN Comparison

Compare VZLA & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VZLA

Vizsla Silver Corp.

HOLD

Current Price

$3.87

Market Cap

2.2B

Sector

N/A

ML Signal

HOLD

Logo Organon & Co.

OGN

Organon & Co.

HOLD

Current Price

$7.70

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VZLA
OGN
Founded
2017
1923
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
VZLA
OGN
Price
$3.87
$7.70
Analyst Decision
Strong Buy
Hold
Analyst Count
2
5
Target Price
$7.00
$14.10
AVG Volume (30 Days)
13.5M
6.1M
Earning Date
12-12-2025
02-12-2026
Dividend Yield
N/A
1.02%
EPS Growth
N/A
N/A
EPS
N/A
1.91
Revenue
N/A
$6,301,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$4.09
Revenue Growth
N/A
N/A
52 Week Low
$1.69
$6.18
52 Week High
$7.19
$17.23

Technical Indicators

Market Signals
Indicator
VZLA
OGN
Relative Strength Index (RSI) 31.33 39.51
Support Level $3.58 $7.74
Resistance Level $5.47 $8.48
Average True Range (ATR) 0.46 0.39
MACD -0.25 -0.17
Stochastic Oscillator 8.17 3.70

Price Performance

Historical Comparison
VZLA
OGN

About VZLA Vizsla Silver Corp.

Vizsla Silver Corp is a junior mineral exploration and development company focused on advancing its Panuco silver-gold project located in Sinaloa, Mexico. The property contains quartz-carbonate veins with workings defining both steeply plunging and sub-horizontal ore shoots. Mineralization occurs as silver sulphides including argentite and acanthite, native gold, electrum and native silver associated with pyrite, minor galena, sphalerite and rare chalcopyrite. It has one operating segment, which is principally mineral exploration.

About OGN Organon & Co.

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

Share on Social Networks: